INTERPACE BIOSCIENCES, INC. Files 8-K on Financials

TL;DR

INTERPACE BIOSCIENCES, INC. (IDXG) filed an 8-K on Aug 1st covering financial results and exhibits.

AI Summary

On August 1, 2024, INTERPACE BIOSCIENCES, INC. filed an 8-K report detailing results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Interpace Diagnostics Group, Inc. and PDI INC.

Why It Matters

This 8-K filing provides crucial updates on INTERPACE BIOSCIENCES, INC.'s financial performance and operational results, which can impact investor decisions.

Risk Assessment

Risk Level: low — This is a routine 8-K filing reporting financial results and exhibits, with no immediate indication of significant new risks.

Key Players & Entities

• INTERPACE BIOSCIENCES, INC. (company) — Registrant
• August 1, 2024 (date) — Date of earliest event reported
• Interpace Diagnostics Group, Inc. (company) — Former company name
• PDI INC (company) — Former company name
• 2001 ROUTE 46 (address) — Business and mail address
• PARSIPPANY, NJ (location) — Business and mail address city and state

FAQ

Filing Documents

• form8-k.htm (8-K) — 37KB
• ex99-1.htm (EX-99.1) — 185KB
• 0001493152-24-030102.txt ( ) — 403KB
• idxg-20240801.xsd (EX-101.SCH) — 3KB
• idxg-20240801_lab.xml (EX-101.LAB) — 34KB
• idxg-20240801_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2024 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Waterview Plaza , Suite 310 2001 Route 46 , Parsippany , NJ 07054 (Address, including zip code, of Principal Executive Offices) (855) 776-6419 Registrant's telephone number, including area code Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered None N/A N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02 Results of Operations and Financial Condition. On August 1, 2024, Interpace Biosciences, Inc. issued a press release announcing its results of operations and financial condition for the second quarter ended June 30, 2024. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference. The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press Release, dated August 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Interpace Biosciences, Inc. By: /s/ Thomas W. Burnell Name: Thomas W. Burnell Title: President and Chief Executive Officer Date: August 2, 2024

View Full Filing

View this 8-K filing on SEC EDGAR